These 10 corporations represent 37% of the MEA market by value. Novo Nordisk’s USD 635M growth is mainly driven by Norditropin (somatropin), Victoza…

Recently appointed as general manager & vice president of Gilead’s UK and Ireland operations, Hilary Hutton-Squire highlights the uniqueness of…

Confirming Eisai’s commitment to keeping its EMEA headquarters in the UK, Gary Hendler, chairman and CEO EMEA, and Nick Burgin, COO and president of…

Between 2010 and 2012 just one of the 139 new medicines to receive market authorisations globally was approved for reimbursement in Serbia, compared…

Lupin’s EMEA President Thierry Volle explains that to fuel growth in the EMEA region, Lupin is investing heavily in transforming the business from a…

Santen’s Head of EMEA explains why the company established their new regional headquarters in Geneva, Switzerland and highlights the three key…

Tuomo Pätsi, President of the EMEA region for Celgene, talks about marking the tenth anniversary of Switzerland as Celgene´s EMEA headquarters;…

Despite the already existing efficiencies in the Italian healthcare system, there is still significant room for improvement. Johnson & Johnson…

Laurence Comte-Arassus, president of Medtronic France, reveals how after the global acquisition of Covidien in January 2015, France is now their…